enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

enGene (NASDAQ:ENGN) issued its earnings results on Monday. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.11, Zacks reports.

Here are the key takeaways from enGene’s conference call:

• Management attributes a combined effect of protocol amendments (T1 re‑resection, TA reinduction, routine biopsy) plus improved clinical execution for an estimated ≈21 percentage‑point improvement in the six‑month complete response rate.
• The program has received RMAT and CDRP designations and aligned the primary endpoint with the FDA to CR “at any time,” and management says ongoing SAP discussions increase confidence toward approval.
• Management states the safety database (the largest in the space at 125 patients) is sufficient and reports tolerability as near “best‑in‑class” with treatment discontinuations around 1–2%.
• They emphasize strong commercial fit in community urology: a non‑viral therapy with simple storage/handling, short clinic administration potentially by APP/staff, favorable buy‑and‑bill economics, and pricing flexibility to maximize market value.
• Company reports a cash runway into the second half of 2028, expects a potential approval in 2027, and plans interim 12‑month data updates (Q2 conference and H2), supporting a near‑term BLA path.

enGene Price Performance

ENGN stock traded down $0.02 during mid-day trading on Tuesday, reaching $7.03. 932,099 shares of the company traded hands, compared to its average volume of 367,692. enGene has a 52-week low of $2.65 and a 52-week high of $12.25. The company has a market capitalization of $470.94 million, a P/E ratio of -3.07 and a beta of -0.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.30 and a quick ratio of 6.30. The company has a fifty day moving average price of $9.54 and a 200-day moving average price of $8.09.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Millennium Management LLC grew its stake in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares in the last quarter. Raymond James Financial Inc. lifted its position in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares during the last quarter. Cresset Asset Management LLC bought a new stake in enGene in the 2nd quarter worth approximately $36,000. Paloma Partners Management Co purchased a new stake in enGene in the second quarter worth approximately $38,000. Finally, Jump Financial LLC bought a new position in enGene during the fourth quarter valued at approximately $121,000. Institutional investors own 64.16% of the company’s stock.

Wall Street Analyst Weigh In

ENGN has been the subject of several research reports. Jefferies Financial Group initiated coverage on enGene in a research note on Friday, January 30th. They issued a “buy” rating and a $28.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research note on Friday, January 9th. UBS Group boosted their price target on shares of enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research note on Wednesday, November 12th. Citizens Jmp boosted their target price on shares of enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of enGene in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, enGene presently has an average rating of “Moderate Buy” and an average price target of $23.29.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.